Friday, July 10, 2026

biotech · SARS-CoV-2 Infection · Breast Cancer

Henlius USA

Henlius USA clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Milpitas, USA HQ
2010 Founded
45 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Milpitas, USA
Founded
2010
Employees
45
Programs
3
Drugs
4
Patents
0
Intelligence · Clinical Programs

Henlius USA projects

3 ClinicalTrials.gov programs sponsored by Henlius USA.

Henlius USA has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Azvudine

    Shanghai Henlius Biotech

    SARS-CoV-2 Infection

    phase 3 small molecule active

    1 trial
  2. HLX02

    Shanghai Henlius Biotech

    Breast Cancer

    phase 3 mab completed

    1 trial
  3. HLX07+carboplatin+pemetrexed

    Shanghai Henlius Biotech

    HLX07, nsqNSCLC, High EGFR Expression

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Henlius USA have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.